Filing summary
Entity and period: The supplied filing is Unum Therapeutics Inc.’s Form 10-K for the fiscal year ended December 31, 2019, filed March 26, 2020. It is not identified as a Cogent Biosciences filing; the filing names Unum and lists ticker UMRX. The requested company and the filing therefore do not match.
Business context and reporting period
Unum was a clinical-stage biopharmaceutical company developing engineered T-cell therapies. Its stated strategic focus was shifting to BOXR1030, a preclinical GPC3-targeted cell therapy incorporating the GOT2 transgene, intended to improve T-cell function in solid tumors. The company had no approved products and no product-sale revenue. Its reported revenue came from its Seattle Genetics collaboration.
Financial performance and liquidity
| Metric | FY 2019 | FY 2018 |
|---|---|---|
| Collaboration revenue | $22.5 million | $9.7 million |
| Research and development expense | $43.7 million | $38.3 million |
| General and administrative expense | $11.0 million | $7.5 million |
| Operating loss | $32.2 million | $36.0 million |
| Net loss | $31.8 million | $34.5 million |
| Net loss per share | $1.04 | $1.39 |
| Cash used in operating activities | $41.5 million | $32.5 million |
- At year-end, cash and cash equivalents were $37.4 million, marketable securities were nil, and working capital was $27.3 million. Total assets were $49.4 million and total liabilities were $17.7 million.
- No term-loan borrowings were outstanding; up to $15 million remained available under the Pacific Western Bank facility, subject to its terms. The facility is secured by substantially all assets other than intellectual property.
- Operating cash use increased year over year. Investing activities provided $23.2 million, principally from maturities and sales of marketable securities; financing activities provided $0.1 million. Cash, cash equivalents and restricted cash fell by $18.2 million during 2019.
- Revenue was entirely collaboration revenue; product gross margin is not applicable. The filing reports no product sales.
Material changes and unusual items
- R&D expense increased $5.4 million and G&A expense increased $3.5 million year over year, while the net loss narrowed by $2.7 million. Higher collaboration revenue partly offset increased operating expenses.
- Fourth-quarter 2019 revenue was $15.3 million and the quarter reported net income of $2.3 million, despite a full-year net loss. The filing attributes the Q4 result to a cumulative adjustment in estimated Seattle Genetics collaboration revenue and costs to complete after suspension of the related clinical program. This was not product-sale revenue.
- Deferred revenue from the collaboration declined to $1.3 million at year-end from $17.9 million in 2018. The company estimated approximately $1 million remained to be recognized through 2020.
- In January 2020, Unum and Seattle Genetics terminated their collaboration. Under the termination terms, Seattle Genetics paid $5.75 million, returned its 831,847 Unum shares, and paid eligible research and development costs through the effective date; Unum remained responsible for trial wind-down expenses. The payment and share return were to be accounted for in 2020.
- In March 2020, Unum announced a workforce reduction of approximately 60% (43 employees) and a concentration of resources on BOXR1030 and the BOXR platform. It targeted an IND filing for BOXR1030 in late 2020. The company estimated approximately $2 million of one-time severance and termination costs.
Outlook, risks and contingencies
- Going concern and funding: The auditor’s report includes a substantial-doubt paragraph, and management concluded substantial doubt existed about the company’s ability to continue as a going concern. The filing states both that year-end cash was expected to fund operations into mid-2021 and that cash and available borrowings would not fund expenses and capital requirements through at least 12 months after issuance of the financial statements. Additional capital was necessary, with no assurance it could be obtained on acceptable terms. Financing could dilute shareholders or require rights to be relinquished.
- Runway depends on assumptions: The company said existing cash would not be sufficient to complete a planned Phase 1 BOXR1030 trial. It had a shelf registration allowing offerings up to $150 million and a $50 million at-the-market sales agreement, but reported no sales under that agreement by year-end.
- Subsequent financing and strategic review: In March 2020, the company entered into an agreement allowing it to sell up to $25 million of shares to Lincoln Park Capital, subject to conditions, and issued 726,382 shares as a commitment fee. It also began exploring strategic alternatives, including possible financing, acquisition, business combination, licensing or other transactions; no transaction was assured.
- Clinical and regulatory risk: BOXR1030 remained preclinical; positive animal and laboratory findings do not establish human safety or efficacy. The company planned to conclude its four legacy Phase 1 ACTR studies. In one HER2+ study, all three treated patients discontinued after disease progression at the first response assessment. In the rituximab combination study, 8 of 20 patients had a complete response at first assessment as of November 2019, but follow-up was limited and the company later planned to end the program.
- Other risks: Key exposures include clinical failure or toxicity, manufacturing and supply-chain constraints, competition, intellectual-property uncertainty, dependence on external vendors, COVID-19-related disruptions, and possible Nasdaq delisting. Nasdaq had notified the company that its bid price was below $1.00; the initial compliance deadline was June 29, 2020.
- The company reported no material legal proceedings. Its auditor issued an unmodified opinion on the financial statements but did not opine on internal control effectiveness; management reported disclosure controls and internal control over financial reporting were effective at year-end.
Most important facts for investors to verify
- Confirm the issuer: this filing is for Unum Therapeutics (UMRX), not Cogent Biosciences.
- Review the full financial statements and notes for the Seattle Genetics revenue true-up, deferred revenue, termination payment and share return accounting.
- Assess available cash, actual post-year-end financing, restructuring cash costs, and the timing and terms of any additional funding against the going-concern warning.
- Check whether the BOXR1030 IND target and preclinical work progressed, and whether the company obtained human-study authorization or reported clinical results.
- Verify the status and outcome of the strategic review, Lincoln Park share sales, and Nasdaq listing compliance.